The report discusses the safety and efficacy of autologous versus allogeneic regenerative cell therapies, emphasizing that both types are manipulated and require rigorous pre-clinical, manufacturing, and clinical studies to assess safety. It argues that the debate should focus on the science behind cell sources rather than safety concerns. The report highlights the advantages of allogeneic therapies, such as lower cost of goods and patient convenience, and discusses various companies and their approaches in the regenerative medicine space.
documents/EFTA01092032.pdf
{}